EasyDraw at home
Nature 477 , 549555 (2011)
W badaniu SURMOUNT-1 dziaania niepodane spowodoway przerwanie terapii u 4,3% (5 mg), 7,1% (10 mg) i 6,2% (15 mg) uczestnikw, w porwnaniu z 2,6% pod placebo (Jastreboff i in., 2022)
35 Clinical data are limited regarding the use of DPP-4 inhibitors to prevent retinopathy
The diagram below illustrates a current snapshot of the intense competition in the weight loss landscape: Visual Credit: Sophia Rawson, Chike Onyia, Nicholas Colaw As the AOM market continues to grow, manufacturers must navigate a range of critical market dynamics, including emerging access dynamics, clinical differentiation needs, patient access challenges, and emerging opportunities for partnerships